Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2017
SIETES contiene 92005 citas

 
 
 1 a 20 de 754 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas
Rochon PA, Vozoris N, Gill SS. The harms of benzodiazepines for patients with dementia . Can Med Assoc J 2017;189:E517-518. [Ref.ID 101525]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Taipale H, Tolppanen A-M, Koponen M, Tanskanen A, Lavikainen P, Sund R, Tiihonen J, Hartikainen S. Risk of pneumonia associated with incident benzodiazepine use among community- dwelling adults with Alzheimer disease. Can Med Assoc J 2017;189:E519-529. [Ref.ID 101524]
4. Cita con resumen
Johnston SL, Szigeti M, Cross M, Brightling C, Chaudhuri R, Harrison T, Mansur A, Robison L, Sattar Z, Jackson D, Mallia P, Wong E, Corrigan C, Higgins B, Ind P, Singh D, Thomson NC, Ashby D, Chauhan A, AZALEA Trial Team. Azithromycin for acute exacerbations of asthma: the AZALEA randomized clinical trial. JAMA 2016;176:1630-7. [Ref.ID 100957]
5. Cita con resumen
Smith JA, Woodcock A. Chronic cough. N Engl J Med 2016;375:1544-51. [Ref.ID 100909]
6. Cita con resumen
Uranga A, España PP, Bilbao A, Quintana JM, Arriaga I, Intxausti M, Lobo JL, Tomás L, Camino J, Nuñez J, Capelastegui A. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med 2016;176:1257-65. [Ref.ID 100750]
7. Cita con resumen
Conway R, Low C, Coughlan RJ, O’Donnell M, Carey JJ. Leflunomide use and risk of lung disease in rheumatoid arthritis: a systematic literature review and metaanalysis of randomized controlled trials . J Rheumatol 2016;43:855-60. [Ref.ID 100497]
8.Enlace a cita original Cita con resumen
Anónimo. Revisión sobre el riesgo de neumonía asociado a la administración de corticoides inhalados para el tratamiento de la EPOC . Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:1. [Ref.ID 100075]
9. Cita con resumen
Barrera CM, Mykietiuk A, Metev H, Nitu MF, Karimjee N, Doreski PA, Mitha I, Tanaseanu CM, Molina JM, Antonovsky Y, Van Rensburg J, Rowe BH, Flores-Figueroa J, Rewerska B, Clark K, Keedy K, Sheets A, Scott D, Horwith G, Das AF, Jamieson B, Fernandes P, Oldach D, for the SOLITAIRE-ORAL Pneumonia Team. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). The Lancet Infectious Diseases 2016;16:421-30. [Ref.ID 99992]
10. Cita con resumen
11. Cita con resumen
Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, Jackson DJ, Baxi SN, Benson M, Burnham C-AD, Cabana M, Castro M, Chmiel JF, Covar R, Daines M, Gaffin JM, Gentile DA, Holguin F, Israel E, Kelly HW, Lazarus SC, Lemanske Jr RF, Meade K, Morgan W, Moy J, Olin T, Peters SP, Phipatanakul W, Pongracic JA, Raissy HH, Ross K, Sheehan WJ, Sorkness C, Szefler SJ, Teague WG, Thyne S, Martinez FD, for the National Heart Lung and Blood Institute's AsthmaNet. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial. JAMA 2015;314:2034-44. [Ref.ID 99768]
12. Cita con resumen
Suissa S, Coulombe J, Ernst P. Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest 2015;148:1177-83. [Ref.ID 99678]
13. Cita con resumen
Kalra L, Irshad S, Hodsoll J, Simpson M, Gulliford M, Smithard D, Patel A, Rebollo-Mesa I, on behalf of the STROKE-INF Investigators. Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial. Lancet 2015;386:1835-44. [Ref.ID 99670]
14. Cita con resumen
Valley TS, Sjoding MW, Ryan AM, Iwashyna TJ, Cooke CR. Association of intensive care unit admission with mortality among older patients with pneumonia. JAMA 2015;314:1272-9. [Ref.ID 99599]
15. Cita con resumen
Anónimo. FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa. FDA U.S. Food and Drug Administration 2015:16 de octubre. [Ref.ID 99566]
17. Cita con resumen
Siemieniuk RAC, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, Alexander PE, Fei Y, Vandvik PO, Guyatt GH. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 2015;163:519-28. [Ref.ID 99389]
18. Cita con resumen
Dawson R, Diacon AH, Everitt D, van Niekerk C, Ronald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp LI, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015;385:1738-47. [Ref.ID 99082]
19.Tiene citas relacionadas Cita con resumen
Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, Winzeler B, Bingisser R, Elsaesser H, Drozdov D, Arici B, Urwyler SA, Refardt J, Tarr P, Wirz S, Thomann R, Baumgartner C, Duplain H, Burki D, Zimmerli W, Rodondi N, Mueller B, Christ-Crain M. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015;385:1511-8. [Ref.ID 99063]
20.Tiene citas relacionadas Cita con resumen
Annane D. Corticosteroids and pneumonia: time to change practice. Lancet 2015;385:1484-5. [Ref.ID 99060]
Seleccionar todas
 
 1 a 20 de 754 siguiente >>